"It's that invisible illness": Patient and clinician perspectives on outcomes in pulmonary arterial hypertension treatment.
outcomes
pulmonary hypertension
qualitative research
Journal
Pulmonary circulation
ISSN: 2045-8932
Titre abrégé: Pulm Circ
Pays: United States
ID NLM: 101557243
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
07
03
2023
revised:
27
04
2023
accepted:
28
04
2023
pubmed:
14
5
2023
medline:
14
5
2023
entrez:
14
5
2023
Statut:
epublish
Résumé
Knowledge of what outcomes are most meaningful to pulmonary arterial hypertension (PAH) stakeholders is limited. In this qualitative study, patients and clinicians endorsed personalized physical activity, symptoms, and psychosocial well-being as key outcomes to assess PAH treatment response, yet few are routinely measured in PAH clinical trials.
Identifiants
pubmed: 37180826
doi: 10.1002/pul2.12236
pii: PUL212236
pmc: PMC10166884
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12236Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL163402
Pays : United States
Informations de copyright
© 2023 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.
Déclaration de conflit d'intérêts
S. M. K. has received funding from Aerovate, Acceleron, Janssen, Regeneron, and Vivus for consulting. He has received funding from United Therapeutics to serve on a Data Safety and Monitoring Board. He has received research support “in kind” from PhysIQ.